Prognostic and Clinicopathological Role of PD-L1 in Endometrial Cancer: A Meta-Analysis

Prognostic value of PD-L1 expression in patients with pancreatic cancer

(2019) Ying Hu et al.   MEDICINE

PD-1/PD-L1 pathway: Basic biology and role in cancer immunotherapy

(2019) Arash Salmaninejad et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Prognostic and Clinicopathological Significance of PD-L1 in Patients With Bladder Cancer: A Meta-Analysis

(2019) Lei Zhu et al.   Frontiers in Pharmacology

The prognostic role of programmed cell death-ligand 1 expression in non-small cell lung cancer patients: An updated meta-analysis

(2018) Guangzhi Ma et al.   CLINICA CHIMICA ACTA

Prognostic implication of programmed cell death 1 protein and its ligand expressions in endometrial cancer

(2018) Jisup Kim et al.   GYNECOLOGIC ONCOLOGY

The clinicopathological and prognostic significance of PD-L1 expression in pancreatic cancer: A meta-analysis

(2018) He-Li Gao et al.   Hepatobiliary & Pancreatic Diseases International

Regulation and Function of the PD-L1 Checkpoint

(2018) Chong Sun et al.   IMMUNITY

Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy

(2018) Kui Li et al.   JOURNAL OF DRUG TARGETING

Expression of Immunomodulatory Molecules PD-1, PD-L1, and PD-L2, and their Relationship With Clinicopathologic Characteristics in Endometrial Cancer

(2018) Nuran Sungu et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY

Tumor-Intrinsic PD-L1 Signaling in Cancer Initiation, Development and Treatment: Beyond Immune Evasion

(2018) Peixin Dong et al.   Frontiers in Oncology

High PD-L1 expression in the tumour cells did not correlate with poor prognosis of patients suffering for oral squamous cells carcinoma: A meta-analysis of the literature

(2018) Giuseppe Troiano et al.   CELL PROLIFERATION

Programmed Death Ligand 1 Expression Among 700 Consecutive Endometrial Cancers

(2017) Zaibo Li et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study

(2017) Patrick A. Ott et al.   JOURNAL OF CLINICAL ONCOLOGY

Elements of cancer immunity and the cancer–immune set point

(2017) Daniel S. Chen et al.   NATURE

PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity

(2017) Sydney R. Gordon et al.   NATURE

Microsatellite instability is a biomarker for immune checkpoint inhibitors in endometrial cancer

(2017) Hitomi Yamashita et al.   Oncotarget

ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer

(2016) Nicoletta Colombo et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Expression of PD-1, PD-L1 and PD-L2 is associated with differentiation status and histological type of endometrial cancer

(2016) Zhongfu Mo et al.   Oncology Letters

Clinicopathological and prognostic significance of programmed cell death ligand 1 (PD-L1) expression in patients with esophageal squamous cell carcinoma: a meta-analysis

(2016) Hai-Xia Qu et al.   Journal of Thoracic Disease

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2009) David Moher et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY